A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

The side effects that come with many cancer treatments can cause people to delay or avoid treatment.

Congruence secures a $5 million grant to advance innovative therapies for GBA1 Parkinson's disease, enhancing hope for ...

Gen Li, president and founder of Phesi, spoke with Pharmaceutical Executive about issues pharma companies are having during ...

The acquisition led by Advent International will see the two AI-powered companies combine forces to improve the healthcare ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic ...